NASDAQ:CODX - Co-Diagnostics Stock Price, Forecast & News

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Co-Diagnostics Inc (NASDAQ:CODX) released its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million. Co-Diagnostics had a negative return on equity of 202.74% and a negative net margin of 5,486.08%. View Co-Diagnostics' Earnings History.

Co-Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Co-Diagnostics.

2 equities research analysts have issued 12-month target prices for Co-Diagnostics' stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Co-Diagnostics' stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 104.1% from the stock's current price. View Analyst Price Targets for Co-Diagnostics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Co-Diagnostics.

News coverage about CODX stock has been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Co-Diagnostics earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Co-Diagnostics.

Co-Diagnostics saw a increase in short interest in November. As of November 29th, there was short interest totalling 549,200 shares, an increase of 18.4% from the November 14th total of 464,000 shares. Based on an average daily trading volume, of 76,700 shares, the short-interest ratio is currently 7.2 days. Currently, 5.1% of the company's stock are sold short. View Co-Diagnostics' Current Options Chain.

Some companies that are related to Co-Diagnostics include Nephros (NEPH), Sensus Healthcare (SRTS), Pro-Dex (PDEX), Apollo Endosurgery (APEN), T2 Biosystems (TTOO), Nephros (NEPHD), Arch Therapeutics (ARTH), BeyondAirInc . (XAIR), SANUWAVE Health (SNWV), Endologix (ELGX), AIT Therapeutics (AITB), Invo Bioscience (IVOB), PAVmed (PAVM), Neovasc (NVCN) and Titan Medical (TMDI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Bausch Health Companies (BHC), Advanced Micro Devices (AMD), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Corbus Pharmaceuticals (CRBP), CytomX Therapeutics (CTMX), Zynerba Pharmaceuticals (ZYNE), AT&T (T), Array Biopharma (ARRY) and bluebird bio (BLUE).

(CODX) raised $9 million in an IPO on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

Co-Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Barclays PLC (0.43%). View Institutional Ownership Trends for Co-Diagnostics.

CODX stock was purchased by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Co-Diagnostics.

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CODX stock can currently be purchased for approximately $0.98.

Co-Diagnostics has a market capitalization of $16.78 million and generates $40,000.00 in revenue each year. Co-Diagnostics employs 22 workers across the globe.View Additional Information About Co-Diagnostics.

The official website for Co-Diagnostics is http://www.codiagnostics.com/.

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE - D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected]